$0.25+0.00 (+0.45%)
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States.
Azitra, Inc. in the Healthcare sector is trading at $0.25. The stock is currently near its 52-week low of $0.10, remaining 51.5% below its 200-day moving average. Technical signals show overbought RSI of 83 and bullish MACD crossover, explaining why AZTR maintains its current current market pressure. The Whystock Score of 10/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04,...
US stocks look set to open higher in Monday's trading session ahead of a raft of earnings coming out
AZTR: Azitra Soars After First Patient Dosed in FDA Fast Track Trial
Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index adding 0.1%
Health care stocks rose Wednesday afternoon with the NYSE Health Care Index adding 0.2% and the Heal